Small Molecules
18 November 2013
Gilead’s Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study18 November 2013
Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation18 November 2013
European Commission Approves Gilead’s Vitekta™, an Integrase Inhibitor for the Treatment of HIV-1 Infection18 November 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL® (posaconazole) Receives FDA Priority Review18 November 2013
RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD18 November 2013
Sanofi Discontinues Clinical Development of Investigational JAK2 Agent Fedratinib (SAR302503)15 November 2013
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 201315 November 2013
Bayer Receives Approval for New Cancer Drug Xofigo® in the EU15 November 2013
FDA Advisory Committee Recommends Approval of HETLIOZ™ for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind14 November 2013
Amakem Presents Positive Top-Line Clinical Results for AMA0076 for Glaucoma at Ophthalmology Innovation Summi14 November 2013
Epizyme’s EPZ-5676 DOT1L Inhibitor Demonstrates Encouraging Initial Findings in an Ongoing Phase 1 Dose Escalation Study14 November 2013
AstraZeneca Announces Initiation of Two Additional Global Studies with Brilinta (Ticagrelor)14 November 2013
Aduro Presents Preclinical Data on Enhanced Anti-Tumor Activity with Small-Molecule Immunotherapy Program14 November 2013
ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis13 November 2013
Anacor Pharmaceuticals Announces Positive Preliminary Results from AN2728 MUSE Study in Pediatric and Adolescent Patients with Atopic Dermatitis13 November 2013
Merck Enters into Further Global Co-Development and Commercialization Agreement for PARP Inhibitor with Chinese R&D Company BeiGene13 November 2013
FibroGen Reports Data from Phase 2 Hemoglobin Correction Study of Roxadustat (FG-4592) in Chinese Patients with Chronic Kidney Disease13 November 2013
FibroGen Announces Analysis of Peritoneal Dialysis Patients with Chronic Kidney Disease from Roxadustat (FG-4592) Incident Dialysis Study12 November 2013
Mid-Stage Clinical Study of Wasting Disease Therapeutic MT-102 Shows Reversal of Cancer-Related WastingNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports